News

– SUDO-550 is a potential best-in-class, orally administered, brain-penetrant TYK2 inhibitor being developed for the treatment of neuroinflammatory diseases. – (…)

PK data analysis in dose-escalation phase indicated exposures of QRL-201 met or exceeded the targeted therapeutic range prompting advancement to (…)

-Development Candidate NDC-0524 is a First-in-Class, Humanized Therapeutic Antibody with High Affinity and Selectivity for Nitrated -Synuclein, which is Rapidly Being (…)

Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery (…)

Explore the transformative advancements in Alzheimer’s research with expert Laurence Barker. Understand why the next decade could see significant leaps (…)

QRL-101 aims to reduce hyperexcitability-induced neurodegeneration, which is present in approximately 50 percent of all ALS patients Completed Phase 1 (…)

Back to School 2024 looks at how neuroscience companies are reducing to practice the concept of human-first discovery Read the (…)

Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing (…)

Back to School 2024: Can biotech write a more successful playbook for translating from target to product? Read the full (…)

The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein degraders into the (…)

Many neurological therapies exhibit dose-limiting side effects, and numerous neurological disease targets remain undruggable because of on-target off-tissue peripheral side (…)

If there’s anyone qualified to analyze an early-stage therapeutic technology and place bets with other people’s money, it’s scientist-turned-venture capitalist (…)

Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme (…)

First presentation of a novel mechanism of action for the degradation of BRD9 – completely differentiated from cereblon- or VHL-based (…)

Designation Supports Accelerated Drug Development for PSP TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers (…)

THN391 demonstrated effectiveness in protecting against vascular and neuronal degeneration – Therini Bio plans to initiate a Phase 1/2a trial (…)

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) — Cerevance, a company focused on developing precision novel therapeutics for central nervous system (…)

Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others (…)

Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a (…)

AVB-101 is an investigational gene therapy designed to deliver a functional copy of the GRN gene directly to the brain, (…)

Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VC efforts like the Dementia Discovery (…)

As we approach the second quarter of 2024, the SV Health Investors Partners investing out of the Dementia Discovery Fund (…)

NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer’s Dementia. Cumulus Neuroscience today announced the enrollment (…)

-Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic (…)

In a recent interview with Laurence Barker, a partner at SV Health Investors and a key figure in the Dementia (…)

Dive into the fascinating world of precision neuroscience with Laurence Barker, Partner at Dementia Discovery Fund – SV Health Investors (…)

The funding will advance two precision TYK2 inhibitors into the clinic for multiple sclerosis, psoriasis and other severe autoimmune and (…)

TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP (…)

First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of (…)

With two new drugs emerging in 2023, could this be the year for neurodegenerative startups to shine? Read the full (…)

Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis Refined focus (…)

Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck This transaction highlights DDF’s attractive strategy of investing in (…)

24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a keybiomarker of neurodegeneration in tauopathies (…)

• AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain (…)

Poster presentations scheduled for the 16th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting on Wednesday October 25th – Friday October 27th, (…)

• AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN (…)

AstronauTx is a biotech company developing new treatments for neurodegenerative conditions based on amplifying the brain’s own physiological protective mechanisms (…)

AstronauTx’s financing is step towards helping millions of people suffering from disease View the article  (…)

DDF Understanding Dementia (…)

Boston, MA – August 28, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision (…)

The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’s and Parkinson’s – conditions (…)

Dementia, the looming health crisis of our time, has long lacked effective treatments. But now, recent drug breakthroughs and the (…)

Boston, MA (US) and London (UK) –June 28th 2023. The Dementia Discovery Fund (DDF), the world’s largest family of specialized venture capital (…)

In conversation with Laurence Barker, a Partner with DDF Can you give me some background on the creation of DDF (…)

Oxford and Cambridge Among Sites Participating in CNS-101 Validation Study BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ (…)

Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and founding investor (…)

AARP-backed research into ALS, Alzheimer’s could lead to dementia drugs View the article  (…)

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and (…)

Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. SOUTH SAN FRANCISCO, (…)

BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build (…)

First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that (…)

QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA (…)

EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round Financing supports clinical activities for Company’s two lead programs (…)

• Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of gene therapies for neurological diseases with (…)

Some of the world’s biggest health challenges do not lend themselves to conventional investment “Dementia is a massive, massive swing (…)

Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase (…)

QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration CAMBRIDGE, Mass., January 5, 2023 – QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision (…)

Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today (…)

First ever study to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients expected to initiate in Canada in (…)

Company discovered selective nitration and regulation of tumor-intrinsic and immuno-oncology targets by several of its proprietary nitrases BRISBANE, Calif., Oct. (…)

Eisai and Biogen report positive results from lecanemab Phase 3 study in Alzheimer’s disease with a statistically significant slowdown in (…)

Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital (…)

• Award reinforces AviadoBio’s position as one of the most promising early-stage biotech companies in the gene therapy industry London, (…)

Searching for protective antibodies in ‘resilient’ people may provide a new approach for discovering drug targets. View the article  (…)

BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build (…)

Pharma pays $25M up front to use target discovery platform as privately-held Cerevance plots path forward for wholly-owned clinical program (…)

Cerevance to concurrently out-license one discovery-stage program Boston, MA – AUGUST 9, 2022 – Cerevance, a private, clinical-stage drug discovery and (…)

SAN FRANCISCO, July 06, 2022 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to (…)

Industry veteran brings proven track record in building successful businesses and leading high-performance teams across large pharmaceutical, biotech, and specialty (…)

Cambridge, UK, 31 May 2022: Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on (…)

• FDA and EC decisions reinforce severity of unmet medical need with this rare, aggressive form of dementia • AviadoBio (…)

Craig Thompson Appointed Chief Executive Officer Founder Brad Margus Assumes Role of Executive Chairman of the Board Boston, MA – April (…)

— Grant to fund exploration of potential new biomarker for Parkinson’s disease — BRISBANE, Calif., April 05, 2022 (GLOBE NEWSWIRE) (…)

Demonstrates the Power of Cerevance’s Deep Understanding of Specific Human Brain Cell Types Boston, MA – March 31, 2022 – Cerevance, (…)

The coronavirus gave us a blueprint for tackling a health crisis: cut red tape and fund more research — but (…)

By targeting the DNA damage repair pathway, the U.K. biotech hopes to stop the formation of mutated HTT, not clean (…)

-Company Identifies Potential New Biomarker And Diagnostic For Parkinson’s Disease- SAN FRANCISCO, March 18, 2022 (GLOBE NEWSWIRE) — Nitrase Therapeutics, Inc. (…)

– Esteemed Harvard Medical School Professor Emeritus and HHMI Investigator, Dr. David Clapham, brings world class expertise on ciliary ion (…)

Dr. Ivarsson is currently Chief Development Officer at Moderna and led clinical trials of the company’s Covid-19 vaccineCambridge, UK – (…)

Series A led by New Enterprise Associates (NEA) and co-led by Monograph Capital follows seeding by Advent Life Sciences, Dementia (…)

– Company targets DNA mismatch repair pathways to slow neurodegeneration in Huntington’s Disease and other triplet repeat disorders – LoQus23’s (…)

–Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer—San Francisco, CA – November 2, 2021 – Nitrase Therapeutics, Inc. (…)

By loading the video, you agree to YouTube’s privacy policy.Learn more Load video Always unblock YouTube PGlmcmFtZSBsb2FkaW5nPSJsYXp5IiB3aWR0aD0iMTAwJSIgaGVpZ2h0PSI0ODAiIHNyYz0iaHR0cHM6Ly93d3cueW91dHViZS1ub2Nvb2tpZS5jb20vZW1iZWQvTi14WWhGb3FjeUkiIGZyYW1lYm9yZGVyPSIwIiBhbGxvdz0iYWNjZWxlcm9tZXRlcjsgYXV0b3BsYXk7IGVuY3J5cHRlZC1tZWRpYTsgZ3lyb3Njb3BlOyBwaWN0dXJlLWluLXBpY3R1cmUiIGFsbG93ZnVsbHNjcmVlbj0iIj48L2lmcmFtZT4= If we want (…)

QRL-201 is a first-in-class molecule that rescues STATHMIN-2 loss of function in motor neuron disease models in the presence of (…)

BELFAST, Northern Ireland, Sept. 14, 2021 /PRNewswire/ — Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical (…)

Dr Thirkettle is a seasoned life sciences executive with deep experience and a proven track record in building successful novel (…)

GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, (…)

Three years later, Dementia Discovery Fund now backs 18 companies seeking treatments View the article  (…)

Industry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly (…)

We are delighted to share the news that Kate Bingham, Managing Partner in the SV Biotech team, has been recognised in (…)

Biocentury article (…)

Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics, (…)

CAMBRIDGE, MA – June 9, 2021 – Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to (…)

Boston, MA (US) and London (UK) – June 7th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in, (…)

New Company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression Cambridge, UK, 2nd June 2021: Transine Therapeutics (…)

Vikas Sharma, Ph.D., Shirley Lasch, and Tim O’Brien join team dedicated to developing new treatments for ALS and other genetically (…)

Strengthens investor syndicate with SV’s Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs (…)

Boston, MA (US) and London (UK) – May 5th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in, and (…)

Proceeds to be used to advance next-generation integrated physiological and digital biomarker platform that provides clinical trial data and AI-powered (…)

Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health (…)

World-recognized experts Dr. Lynne Hughes and Dr. James Summers appointed as Venture Partners Boston, MA (US) and London (UK) – April (…)

Cambridge, MA, 17, March 2021 Amathus Therapeutics announced today a strategic collaboration with Merck, known as MSD outside the United (…)

Alchemab using unique approach to explore adaptive immunity – identifying naturally protective antibodies in ‘resilient patients’ to specific diseases Innovate (…)

CAMBRIDGE, Mass., February 2, 2021— QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) (…)

Exclusive worldwide license and collaboration agreement to discover, develop and commercialize small molecule drug candidates against several RNA targets Partnership (…)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox (…)

Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia Boston, MA – (…)

Nitrome SAB composed of esteemed experts and key scientific thought leaders in neurobiology and drug development SAN FRANCISCO, Nov. 12, (…)

According to Fierce Biotech, what makes QurAlis fierce: There are currently four drugs approved by the U.S. FDA to treat ALS: (…)

The additional proceeds will aid in the development of the company’s NETSseq platform which it is using to discover entirely (…)

QurAlis to in-license lead excitotoxicity targeted ALS therapeutic candidates from LillyCambridge, MA, July 01, 2020 — QurAlis Corporation, a biotech company focused (…)

MANCHESTER, England, June 2, 2020 /PRNewswire/ — The therapeutics biotech AstronauTx announces a partnership with Concept Life Sciences, Contract Research (…)

Funding led by Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery FundCAMBRIDGE, Mass.–(BUSINESS WIRE)–QurAlis Corporation, a biotech company (…)

Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related DiseasesThe (…)

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new (…)

BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) — Cerevance, a private drug discovery and development company focused on brain diseases, (…)

March 23, 2020 at 8:30 AM EDTSOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC) (…)

SV Health Investors announces the appointment of Christian Jung, PhD as Partner in the Dementia Discovery Fund Former Principal at (…)

Press Release: August 12, 2019 AstronauTx secures £6.5 million investment for new approach to dementia therapeutics First company created from (…)

Dementia Discovery Fund launches new research accelerator partnership with the UK Dementia Research Institute at inaugural Annual Forum for Dementia (…)

The Dementia Discovery Fund welcomes Bill Gates’ second investment in Alzheimer’s research. Bill is joining Leonard Lauder, ADDF, the Dolby (…)

Dementia Discovery Fund announces the appointment of Angus Grant PhD as CEODr Grant from Celgene to join DDF in JulyDementia (…)

Includes $60 million new investment from US AARPThe DDF is the world’s largest venture fund focused on a single disease (…)

The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer’s (…)

13 February 2018The DDF welcomes new draft guidance from the FDA that endorses a new approach in Alzheimer’s Disease research (…)

Following last year’s meetings in New York and Cambridge, the DDF are again pleased to be presenting at upcoming Johnson (…)

London, 16 November 2017 – The Dementia Discovery Fund (DDF) today announces an investment from the US National Football League Players (…)

Ness Ziona, Israel June 27, 2017 – Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today (…)

Dementia Discovery Fund Annual Update Nine investments made since launch, collaborations established with world-leading academic institutions, scientific strategy prioritised and (…)

CAMBRIDGE, England & CAMBRIDGE, MA. (June 1, 2017) — Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based (…)

Dementia Discovery Fund to Invest $5 Million in Cerevance to Seek New Treatments for Dementia London and Boston, 3 May (…)

London, UK – 15th March 2017 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments (…)

The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library The DDF and Aptuit enter (…)

UK Department of Health, Alzheimer’s Research UK and major global pharmaceutical companies invest $100 Million Ground breaking collaboration to address (…)

Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in (…)

Tetsuyuki Maruyama joins from Takeda Pharmaceutical Co. Ltd as CSO Laurence Barker from GSK also joins as Chief Business Officer (…)

First investment of Dementia Discovery Fund is in pioneering immuno-modulatory antibody discovery company, Alector LLCAlector LLC is developing antibody drugs (…)